Avenues for antifungal drug discovery and development: where to now?

References

• Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012 Dec 19; 4(165):165rv13.
   PubMed Web of Science ®Google Scholar
• Forsberg K, Woodworth K, and Walters M, et al. Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Medical Mycology. 2019 Jan;57(1):1–2. DOI:https://doi.org/10.1093/mmy/myy054.
   Google Scholar
• van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013 Aug;57(4):513–520.
   PubMed Web of Science ®Google Scholar
• Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev. 2009;22(2):291–321.
   PubMed Web of Science ®Google Scholar
• Sagatova AA, Keniya MV, Wilson RK, et al. Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase. Sci Rep. 2016 May 18; 6:26213.
   PubMedGoogle Scholar
• McCarthy MW, Kontoyiannis DP, Cornely OA, et al. Novel agents and drug targets to meet the challenges of resistant fungi. J Infect Dis. 2017;216(suppl_3):S474–S83.
   PubMed Web of Science ®Google Scholar
• Abadio AKR, Kioshima ES, Teixeira MM, et al. Comparative genomics allowed the identification of drug targets against human fungal pathogens. BMC Genomics. 2011 Jan 27; 12(1):75.
   PubMedGoogle Scholar
• Koselny K, Green J, DiDone L, et al. The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis. Antimicrob Agents Chemother. 2016 Dec;60(12):7115–7127.
   PubMed Web of Science ®Google Scholar
• Bouz G, Doležal M. Advances in antifungal drug development: an up-to-date mini review. Pharmaceuticals (Basel). 2021 Dec 16; 14(12):1312.
   PubMedGoogle Scholar
• Li Z, Tu J, Han G, et al. Novel Carboline Fungal Histone Deacetylase (HDAC) inhibitors for combinational treatment of azole-resistant candidiasis. J Med Chem. 2021 Jan 28; 64(2):1116–1126.
   PubMedGoogle Scholar
• Roscetto E, Contursi P, Vollaro A, et al. Antifungal and anti-biofilm activity of the first cryptic antimicrobial peptide from an archaeal protein against Candida spp. clinical isolates. Sci Rep. 2018 Dec 4; 8(1):17570.
   PubMedGoogle Scholar
• Vij R, Hube B, Brunke S. Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria. Comput Struct Biotechnol J. 2021;19:1244–1252.
   PubMedGoogle Scholar
• Graham CE, Cruz MR, Garsin DA, et al. Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of Candida albicans. Proc Natl Acad Sci USA. 2017 Apr 25; 114(17):4507–4512.
   PubMed Web of Science ®Google Scholar
• Jorjão AL, de Oliveira FE, Leão MV, et al. Live and heat-killed Lactobacillus rhamnosus ATCC 7469 may induce modulatory cytokines profiles on macrophages RAW 264.7. Sci World J. 2015;2015:716749.
   Google Scholar
• Rossoni RD, Fuchs BB, de Barros PP, et al. Lactobacillus paracasei modulates the immune system of Galleria mellonella and protects against Candida albicans infection. PLoS One. 2017;12(3):e0173332.
   PubMed Web of Science ®Google Scholar
• Posch W, Wilflingseder D, Lass-Flörl C. Immunotherapy as an antifungal strategy in immune compromised hosts. Curr Clin Microbiol Rep. 2020;7(3):57–66.
   Google Scholar
• Wan L, Zhang Y, Lai Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial. J Clin Oncol. 2015 Dec 1;33(34):3999–4006.
   PubMedGoogle Scholar
• Stephen-Victor E, Karnam A, Fontaine T, et al. Aspergillus fumigatus cell wall α-(1,3)-Glucan stimulates regulatory T-cell polarization by inducing PD-L1 expression on human dendritic cells. J Infect Dis. 2017 Dec 5;216(10):1281–1294.
   PubMedGoogle Scholar
• Wurster S, Bandi A, Beyda ND, et al. Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother. 2019 Jul 1 74(7):1904–1910.
   PubMed Web of Science ®Google Scholar
• Ben Yaakov D, Rivkin A, Mircus G, et al. Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis. J Antimicrob Chemother. 2016 Apr;71(4):946–952.
   PubMedGoogle Scholar
• Pfaller MA, Watanabe N, Castanheira M, et al. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. J Antimicrob Chemother. 2011 Nov;66(11):2581–2584.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013 Feb;57(2):1065–1068.
   PubMed Web of Science ®Google Scholar
• Pukkila-Worley R, Holson E, Wagner F, et al. Antifungal drug discovery through the study of invertebrate model hosts. Curr Med Chem. 2009;16(13):1588–1595.
   PubMed Web of Science ®Google Scholar
• Apgar JM, Wilkening RR, Greenlee ML, et al. Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin. Bioorg Med Chem Lett. 2015;25(24):5813–5818.
   PubMedGoogle Scholar
• Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: a novel oral glucan synthase inhibitor. Med Mycol. 2020 Jul 1;58(5):579–592.
   PubMed Web of Science ®Google Scholar
• Wring S, Murphy G, Atiee G, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions. J Clin Pharmacol. 2018 Oct;58(10):1305–1313.
   PubMed Web of Science ®Google Scholar
• Thompson GR, Soriano A, Skoutelis A, et al. rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2021 Dec 6;73(11):e3647–e55.
   PubMed Web of Science ®Google Scholar
• Rauseo AM, Coler-Reilly A, Larson L, et al. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7(2):ofaa016.
   PubMed Web of Science ®Google Scholar
• Miesel L, Lin KY, Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK/PD pharmacometrics of rezafungin efficacy. Pharmacol Res Perspect. 2019 Dec;7(6):e00546.
   PubMed Web of Science ®Google Scholar
• Oliver JD, Sibley GEM, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12809–12814.
   PubMed Web of Science ®Google Scholar
• McCarty TP, Pappas PG. Antifungal pipeline. Front Cell Infect Microbiol. 2021;11:732223.
   PubMedGoogle Scholar
• Wiederhold NP, Najvar LK, Fothergill AW, et al. The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans. Antimicrob Agents Chemother. 2015 Jan;59(1):690–692.
   PubMed Web of Science ®Google Scholar
• Hata K, Horii T, Miyazaki M, et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother. 2011 Oct;55(10):4543–4551.
   PubMed Web of Science ®Google Scholar
• Ellsworth M, and Ostrosky-Zeichner L. Isavuconazole: mechanism of action, clinical efficacy, and resistance. Journal of Fungi. DOI:https://doi.org/10.3390/jof6040324.
   Google Scholar
• Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021 Jun;21(6):e149–e62.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2017 Feb 17; 8(2):169–185.
   PubMed Web of Science ®Google Scholar
• Wood KB, Wood KC, Nishida S, et al. Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. Cell Rep. 2014 Mar 27; 6(6):1073–1084.
   PubMed Web of Science ®Google Scholar
• Baym M, Stone LK, Kishony R. Multidrug evolutionary strategies to reverse antibiotic resistance. Science. 2016 Jan 1; 351(6268):aad3292.
   PubMed Web of Science ®Google Scholar
• Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018 Feb 28 16(1):29.
   PubMed Web of Science ®Google Scholar
• Thompson GR III, Boulware DR, Bahr NC, et al. Noninvasive testing and surrogate markers in invasive fungal diseases. Open Forum Infect Dis. 2022;9(6):ofac112.
   PubMedGoogle Scholar
• Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. J Infect Dis. 2020 Aug 5 222(Suppl 3):S175–s98.
   PubMedGoogle Scholar
• Casadevall A, Kontoyiannis DP, Robert V. Environmental Candida auris and the global warming emergence hypothesis. mBio. 2021 Mar 16;12(2). DOI:https://doi.org/10.1128/mBio.00360-21.
   Google Scholar
• Pfavayi LT, Denning DW, Baker S, et al. Determining the burden of fungal infections in Zimbabwe. Sci Rep. 2021 Jun 24; 11(1):13240.
   PubMedGoogle Scholar